- Conditions
- Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
- Interventions
- PF-08634404, Bevacizumab, Chemotherapy
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 254
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 991
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
- Interventions
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Not listed
- Enrollment
- 99,999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2041
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
- Interventions
- Lepodisiran Sodium, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 222
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
- Conditions
- Post-Ischemic Stroke
- Interventions
- Placebo, dalfampridine-ER 7.5mg, dalfampridine-ER 10mg
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 70
- States / cities
- Gilbert, Arizona • Berkeley, California • Long Beach, California + 61 more
- Conditions
- Neuroendocrine Tumors
- Interventions
- 177Lu-DOTA0-Tyr3-Octreotate
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 41
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 33 more
- Conditions
- Covid19
- Interventions
- Fluticasone, Placebo
- Drug · Other
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 87
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
- Conditions
- Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative
- Interventions
- Screening Mammography, Biospecimen Collection
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 514
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Glendale, Arizona + 341 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Efpeglenatide (SAR439977), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 79
- States / cities
- Sheffield, Alabama • Gilbert, Arizona • Surprise, Arizona + 69 more
- Conditions
- Subjects Treated With Karma Fixation System as Part of Their Spine Surgery
- Interventions
- Not listed
- Lead sponsor
- Spinal Elements
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Gilbert, Arizona • Jacksonville, Florida • Shreveport, Louisiana + 1 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Vincristine, Rescue medication, Methylprednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 65
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 60 more
- Conditions
- Breast Cancer
- Interventions
- Radiation, No Radiation
- Radiation · Other
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 2,138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 451
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
- Conditions
- Urothelial Carcinoma
- Interventions
- disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 89
- States / cities
- Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Interventions
- M7824, Placebo, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
- Interventions
- disitamab vedotin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 75
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more
- Conditions
- Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- LCZ696
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 22
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 18 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
- Conditions
- Ventricular Fibrillation, Ventricular Tachycardia, Low Cardiac Output
- Interventions
- EMBLEM S-ICD System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
- Conditions
- Psoriatic Arthritis, Obesity
- Interventions
- Ixekizumab, Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 81
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 415
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
- Conditions
- Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Apache Junction, Arizona + 60 more
- Conditions
- Multiple Myeloma (MM)
- Interventions
- Cemsidomide, Elranatamab
- Drug · Biological
- Lead sponsor
- C4 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Sacramento, California • Santa Monica, California + 16 more
- Conditions
- Covid19
- Interventions
- Fluvoxamine, Placebo
- Drug · Other
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 91
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more